DNA vaccines are third-generation vaccines and consist of a small circular piece (DNA sequence) of bacterial DNA, which is used for the immunization. DNA vaccine is used for protecting humans against disease by injecting them with genetically engineered DNA to produce an immunological response by activating the host against the gene delivered. DNA vaccines are advantageous over traditional vaccines as the expression of native virus with the antigen is more similar as compared to conventional vaccines, and several antigen or proteins can be delivered in a single dose. In addition, large-scale production can be carried out at a cost lower than conventional method of vaccines. The global potential analysis of DNA vaccines market is expected to account $3,762 million in 2020 and reach $9,337 million by 2030, growing at a CAGR of 9.5% from 2020 to 2030.
The global potential analysis of human DNA vaccine market is segmented based on forecast scenario analysis and region. Based on forecast scenario analysis, it is divided into rapid growth scenario, moderate growth scenario, and low growth scenario. The market analysis based on region includes North America, Europe, Asia-Pacific, and LAMEA.
KEY MARKET BENEFITS
In-depth study of the global potential market for DNA vaccines is conducted based on the current disease prevalence, target population, and pricing for generating market size and forecast from 2020 to 2030.
Potential analysis of opportunities is evaluated to understand different aspects of DNA vaccines that are currently under various phases of clinical trials along with the variants that would gain prominence in the future.
Vaccine pipeline products against DNA, which are under various clinical stages, are covered.
Key market players are profiled and their strategies are analyzed thoroughly to understand various technologies adopted to manufacture DNA vaccines.
KEY MARKET SEGMENTS
By Forecast Scenario Analysis
Rapid Growth Scenario
Moderate Growth Scenario
Low Growth Scenario
By Region
North America
Europe
Asia-Pacific
LAMEA
KEY PLAYERS
Inovio Pharmaceuticals, Inc.
GeneOne Life Science Inc.
MedImmune
Immunomic Therapeutics, Inc.
Astellas Pharma, Inc.
Pharos Biologicals
Sanofi S.A.
F. Hoffmann-La Roche AG
CureVac
Boehringer Ingelheim GmbH